Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers

Table 2

miRNAs found deregulated in hepatocellular carcinoma.

miRNA	Deregulation	Method	Number of subjects	Reference
miR-1, miR-25, miR-92a, miR-206, miR-375, and let-7f	Up	Solexia sequencing, qRT-PCR	120 HCC, 135 HBV, 48 HCV, and 210 controls	[32]
miR-21	Up	qRT-PCR	126 HCC, 30 CHB, and 50 healthy subjects	[33]
miR-143 and miR-215	Up	qRT-PCR/TaqMan miRNA assays	95 HCC, 118 hepatitis carriers, and 127 controls	[34]
miR-155	Up	qRT-PCR	10 HCV-HCC, 34 HCV, 12 NASH, and 7 healthy subjects	[35]
miR-15b and miR-130b	Up	qRT-PCR	57 HCC, 29 HBC, and 30 controls	[36]
miR-125b	Up	BioMark™ Dynamic Array	20 HBV-positive HCC, 24 CHB, 22 HBV-positive cirrhosis, and 28 controls	[37]
miR-221, miR-222, and miR-224	Up	qRT-PCR	46 HCC and 20 controls	[38]
miR-500	Up	qRT-PCR	10 HCC	[39]
miR-16 and miR-199a	Down	qRT-PCR	105 HCC patients, 107 CLD, and 71 controls	[40]
miR-122	Down	qRT-PCR	62 HCC, 48 CLD, and 34 controls	[41]
miR-29	Down	qRT-PCR	17 HCC and 17 controls	[42]
miR-152	Down	qRT-PCR	89 HCC and 89 controls	[43]
miR-200a	Down	qRT-PCR	41 HCC and 41 controls	[43]
miR223-3p	Down	BioMark Dynamic Array	20 HBV-positive HCC, 24 CHB, 22 HBV-positive cirrhosis, and 28 controls	[37]

CHB: chronic hepatitis B; NASH: nonalcoholic steatohepatitis; HBC: hepatitis B carriers; CLD: chronic liver diseases.